Endocrine treatment with 2 years of tamoxifen versus 2 years of exemestane in postmenopausal patients with high-risk early breast cancer and persisting circulating tumor cells: first results of the SUCCESS C endocrine treatment sub-study - Schochter, Fabienne; Rack, Brigitte K.; Tzschaschel, Marie; Polasik, Arkadius; Andergassen, Ulrich; Trapp, Elisabeth; Alunni-Fabbroni, Marianna; Schneeweiss, Andreas; Müller, Volkmar; Pantel, Klaus; Gade, Jörg; Lorenz, Ralf; et al. (Oncology research and treatment, 2018)
Published online: February 27, 2018